Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)

被引：0

作者：

Blauvelt, Andrew ^{[1
]}

Thyssen, Jacob P. ^{[2
]}

Guttman-Yassky, Emma ^{[3
]}

Bieber, Thomas ^{[4
]}

Carrascosa, Jose Manuel ^{[5
]}

Simpson, Eric ^{[6
]}

Rosmarin, David ^{[7
]}

Elmaraghy, Hany ^{[8
]}

Meskimen, Eric ^{[8
]}

Natalie, Chitra R. ^{[8
]}

Liu, Zhuqing ^{[8
]}

Xu, Chenjia ^{[8
]}

Pierce, Evangeline ^{[8
]}

Morgan-Cox, MaryAnn ^{[8
]}

Silverberg, Jonathan, I ^{[9
]}

机构：

[1] Oregon Med Res Ctr, Portland, OR 97223 USA

[2] Univ Copenhagen, Bispebjerg Hosp, Copenhagen, Denmark

[3] Icahn Sch Med Mt Sinai, New York, NY USA

[4] Univ Hosp Bonn, Bonn, Germany

[5] UAB, Germans Trias i Pujol Univ Hosp, IGTP, Barcelona, Spain

[6] Oregon Hlth & Sci Univ, Portland, OR USA

[7] Tufts Univ, Sch Med, Boston, MA USA

[8] Eli Lilly & Co, Indianapolis, IN USA

[9] George Washington Univ, Sch Med & Hlth Sci, Washington, DC USA

来源：

BRITISH JOURNAL OF DERMATOLOGY | 2023年 / 188卷

关键词：

monotherapy; atopic dermatitis; moderate-to-severe; lebrikizumab; interleukin (IL)-13;

D O I：

10.1093/bjd/ljac140.018

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

322

引用

页数：2

共 50 条

[31] Safety and efficacy of upadacitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis: results from two pivotal, phase III, randomized, double-blinded, monotherapy, placebo-controlled studies (Measure Up 1 and Measure Up 2)
Guttman-Yassky, E.
Teixeira, H. D.
Simpson, E. L.
Papp, K. A.
Pangan, A. L.
Blauvelt, A.
Thaci, D.
Chu, C. Y.
Hong, H. C.
Katoh, N.
Paller, A. S.
Calimlim, B.
Gu, Y.
Hu, X.
Liu, M.
Yang, Y.
Tenorio, A. R.
Chu, A. D.
Irvine, A. D.
BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : E62 - E62
[32] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB159 - AB159
[33] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide A.
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan D.
Pierce, Evangeline
Elmaraghy, Hany
Pillai, Sreekumar
Dawson, Zach
Chen, Sherry
Armengol, Clara
Siegfried, Elaine
Weidinger, Stephan
JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
[34] Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials
Hebert, Adelaide
Flohr, Carsten
Hong, H. Chih-ho
Irvine, Alan
Pierce, Evangeline
Elmaraghy, Hany
Xu, Wen
Pillai, Sreekumar
Dawson, Zach
Siegfried, Elaine
Weidinger, Stephan
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[35] A phase 2b, randomized, double-blinded, parallel-group, placebo-controlled, international, multicenter, study to evaluate the efficacy and safety of rezpegaldesleukin in adults with moderate-to-severe atopic dermatitis
Gooderham, Melinda
Lynde, Charles
Alam, Maryam Shayesteh
Sadick, Neil
Rohan, Craig A.
Werschler, William Philip
Hebert, Adelaide A.
Laquer, Vivian T.
Sauder, Maxwell
Del Rosso, James Q.
Rodgers, Timothy
Tan, Ricardo
Schleicher, Stephen
Murrell, Dedee F.
Fernandez-Penas, Pablo
Reich, Adam
Gkalpakiotis, Spyridon
Ruiz, Juan Ruano
Wollenberg, Andreas
Szepietowski, Jacek C.
Sticherling, Michael
Weyergraf, Ansgar J.
Hadzavdic, Suzana Ljubojevic
Baran, Wojciech
Vilchez, Trinidad Montero
Eniko, Telegdy
Sebastian, Michael
Chaudhry, Sohail
Lee, Zachary
Yu, Danni
Liu, Yi
Waltz, Wang
Gilbert, Jenny
Elko-Simms, Lucinda M.
Fanton, Christie
Jue, Charleen
Tagliaferri, Mary
Zalevsky, Jonathan
Rosmarin, David
BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : 105 - 107
[36] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
Torrelo, A.
Rewerska, B.
Paller, Amy
Prakash, A.
Zhu, D.
Pontes, M.
Wu, Wen-Shuo
Eichenfield, Lawrence F.
Boecker, Ulrike
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
[37] Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials
Yosipovitch, Gil
Lio, Peter
Rosmarin, David
Legat, Franz
Carrascosa, Jose Manuel
Meskimen, Eric
Casillas, Marta
Pierce, Evangeline
Liu, Zhuqing
Zhong, Jinglin
Staender, Sonja
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB188 - AB188
[38] EFFICACY AND SAFETY OF IXEKIZUMAB IN A RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 3B CLINICAL TRIAL IN PATIENTS WITH MODERATE-TO-SEVERE GENITAL PSORIASIS
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Yang, F. E.
Bleakman, Potts A.
JOURNAL OF SEXUAL MEDICINE, 2018, 15 (02): : S6 - S7
[39] Efficacy and Safety of Ixekizumab in a Randomized, Double-Blinded, Placebo-Controlled, Phase 3b Clinical Trial in Patients with Moderate-to-Severe Genital Psoriasis
Ryan, Caitriona
Menter, Alan
Guenther, Lyn
Blauvelt, Andrew
Bissonnette, Robert
Yang, Fan Emily
Bleakman, Alison Potts
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 13 - 14
[40] Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled, phase 3b clinical trial in patients with moderate-to-severe genital psoriasis
Ryan, C.
Menter, A.
Guenther, L.
Blauvelt, A.
Bissonnette, R.
Yang, F. E.
Bleakman, A. Potts
Burkhardt, N.
AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2018, 59 : 42 - 42

← 1 2 3 4 5 →